The 2023 Annual Meeting and New Year Gathering of the Jiangxi Provincial Pharmaceutical Industry Association, themed "Welcoming the New Year, Seeking Development, Embarking on a New Journey", was grandly held.

Dragon soars across the four seas, a new era begins. To further strengthen the organizational structure of the Jiangxi pharmaceutical industry and better leverage the association's role in service, bridging, connecting, rights protection, and self-discipline, the 2023 Annual Meeting and New Year Gathering of the Jiangxi Pharmaceutical Industry Association was grandly held at the Nanchang Binjiang Hotel on the morning of March 1st. Entrepreneurs from the Jiangxi pharmaceutical industry gathered together to foster friendships, discuss the future, analyze the situation, share achievements, talk about cooperation, explore development, and jointly promote the development of the pharmaceutical and health industry.

The meeting was chaired by Chen Niandai, President of the Jiangxi Pharmaceutical Industry Association and Chairman of Jiangxi Huiren Pharmaceutical Holdings Co., Ltd. Attending the meeting were Xiong Yan, Deputy Director-level Investigator of the Pharmaceutical Industry Department of the Jiangxi Provincial Department of Industry and Information Technology; Zhang Jingsheng, Vice President of the Jiangxi Pharmaceutical Industry Association, Party Secretary and Chairman of Jiangxi Sanhai Group; Wang Yaohui, Secretary-General of the Jiangxi Pharmaceutical Industry Association; and over 70 leaders from member units of the association.

President Chen Niandai pointed out that the Jiangxi Pharmaceutical Industry Association has been established for 20 years. With the care and support of government departments at all levels, leaders at all levels, and all sectors of society, the association has taken innovative pharmaceutical development as its core, building platforms, integrating resources, and striving to play the role of a bridge and link between the government and enterprises. The association's organizational structure is increasingly sound, its service model is increasingly mature, and the pharmaceutical industry is moving towards standardized and orderly development. Various member units focus on key technologies, closely follow clinical needs, are market-oriented, and driven by technological innovation. Each unit gives full play to its own strengths, works together, and integrates development to make its due contribution to the high-quality development of the pharmaceutical industry in our province. President Chen Niandai stressed that we must keep pace with the times, actively change our thinking, embrace the development trend of the digital economy and artificial intelligence, accelerate the digital transformation of the pharmaceutical industry, improve high-end, intelligent, and green levels, and cultivate new momentum, promote new development, and create new brilliance for the high-quality development of the Jiangxi pharmaceutical industry.

At the meeting, Xiong Yan, Deputy Director-level Investigator of the Pharmaceutical Industry Department of the Provincial Department of Industry and Information Technology, reported on the operation of the pharmaceutical industry in the province in 2023 and interpreted relevant government policies. Xiong Yan stated that the pharmaceutical industry in our province has strong resilience, great potential, and sufficient vitality. We should rely on the obvious advantages of Jiangxi's biopharmaceutical industry in technology, research and development, and market, and accelerate the creation of a competitive biopharmaceutical industrial cluster. It is required to strengthen the leading role of enterprises in technological innovation, increase research and development investment, vigorously apply for innovative pharmaceutical research and development projects, and accurately empower the high-quality development of the pharmaceutical industry in our province. Vice President Zhang Jingsheng reported on the association's financial income and expenditure in 2023, stating that it will continue to ensure the transparency and compliance of finances, optimize resource allocation, and serve member units. Secretary-General Wang Yaohui reported to the conference on the association's work in 2023 and the work plan for 2024. He stated that in 2023, under the joint efforts of all member units, the Provincial Pharmaceutical Industry Association, while closely focusing on the development goals of Jiangxi's pharmaceutical industry, actively played a bridging role, striving to be a good assistant to the government and a helper to its members, and made due contributions to promoting the high-quality development of the pharmaceutical industry in our province. In 2024, the association will adhere to the work ideas of serving government decision-making, serving industry development, and serving member development, further stimulating the vitality of the pharmaceutical industry in our province, boosting confidence, and improving the digitalization, intelligence, and green level of the industry. It will continuously carry out policy publicity and interpretation in the field of the pharmaceutical industry, actively organize exchanges and discussions on the pain points and difficulties of the industry, and strive to create a platform for communication and sharing among member units, creating conditions for member enterprises to participate in industry activities.

At the meeting, leaders from Jiangxi Bioproducts Research Co., Ltd., Jiangxi Luyan Pharmaceutical Co., Ltd., Jiangxi Yiyou Pharmaceutical Co., Ltd., Nanchang Shikong Yueke Technology Co., Ltd., Jiangxi Xinglin Baima Pharmaceutical Co., Ltd., Nanchang Hongyi Pharmaceutical Technology Co., Ltd., Jiangxi Yintao Pharmaceutical Co., Ltd., Guoyao Holding Jiangxi Branch, and the Zhangshu Pharmaceutical Commercial Association actively spoke, exchanging views on the difficulties and hot issues in the development of the pharmaceutical industry. They put forward constructive opinions on aspects such as pharmaceutical compliance, the pharmaceutical industry chain and supply chain development, enterprise resource sharing, enterprise transformation and upgrading, innovative research and development projects, and policy guidance. Participating representatives all hoped that the association would continue to play its role as a bridge and link, actively reflect the industry's needs to relevant government departments, formulate measures and policies to support the development of the industry, and promote the high-quality development of pharmaceutical enterprises in our province. (This article is reprinted from the "Hongyi Pharmaceutical" WeChat official account.)